James Study Could Point the Way to New Triple-Negative Breast Cancer Treatments
A James study could help researchers identify new ways that patients’ own bodies could aid in the treatment of triple-negative breast cancer.
Researchers involved in the study will try to identify patients with triple-negative breast cancer—a form of the disease that lacks three receptors typically targeted by treatment—that are likely to benefit from therapies that activate their immune systems.
“We’re determined to get to the end and really find as many answers as we can,” study leader Daniel Stover, MD, says. “So we’re going to continue this on as long as we need and the patients are able to continue on the study.”